Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis

Table 1 The survival rates of CRS plus IPHC in patients with PC of different malignancies

Authors	Pts	Year	Type of	Tumor type	Drugs, temperature	Median	Survival rate (%)
	n		study		& duration	follow-up time	1 yr	2 yr	3 yr	4 yr	5 yr
Pilati et al[90]	34	2003	Phase II	Colon ca	MMC 26.2 mg (20.1-31.6 mg) CDDP 193.7 mg (170-241.1 mg), 41.5°C (41.2°C-42.1°C), 90 min	14.5 mo (6-34 mo)	68	31	-	-	-
Glehen et al[81]	56	2003	Phase II	CRC, OC, GC, peritoneal Mesothelioma, Pseudomyxoma peritonei, and others	MMC 0.7 mg/kg (max dose 60 mg), CDDP 1 mg/kg (max dose 80 mg), 46°C-48°C, 90 min	544.4 d (133-1680 d)	-	R0: 79.0; R2: 44.7	-	-	-
Verwaal et al[67]	54	2003	Phase III	CRC	MMC 70 mg, 41°C-42°C, 90 min	21.6 mo	67	44	-	-	-
Witkamp et al[60]	29	2001	PhaseI/II	CRC	MMC 35 mg/m2, 40°C-41°C, 90 min	38 mo (26-52 mo)	82	45	23	-	-
Shen et al[84]	77	2004	Phase II	CRC	MMC 40 mg, 40.5°C, 120 min	15 m	56	-	25	-	17
Elias et al[91]	24	2004	Phase II	CRC	LOHP 460 mg/m2 in 2 L/m2, 43°C, 30 min	27.4 mo (18.3-49.6 mo)	83	74	65	-	-
Yonemura et al[92]	107	2005	-	GC	MMC 30 mg, CDDP 300 mg, etoposide 150 mg, 42°C-43°C	46 mo	-	-	-	-	6.7 all pts; 27 R0 pts
Yonemura et al[93]	48	2001	Randomized study	T2-T4 GC	MMC 30 mg, CDDP 300 mg, 42°C-43°C, 60 min	5.5 yr (2.4-10.8 yr)	-	-	-	-	61
Elias et al[94]	30	2006	Phase II	CRC	LOHP 460 mg/m2 in 2 L/m2 of iso-osmotic 5% dextrose, 43°C, 30 min	55 mo (24-80 mo)	97	73	53	49	-
Yan et al[75]	30	2006	-	CRC	-	12 mo	72	64	-	-	-
Glehen et al[78]	53	2004	Phase II	CRC	MMC 40-60 mg, 46°C-48°C, 90 min	60 mo	55	32	-	-	11
Helm et al[95]	18	2007	Retrospective review	Recurrent OC	CDDP 100 mg/m2 or MMC 30-40 mg, 41°C-43°C, 90 min	16.2 mo (6-33 mo)	-	60	-	-	-
Deraco et al[96]	33	2004	phase II	Pseudomyxoma peritonei	CDDP 25 mg/m2 per L plus MMC 3.3 mg/m2 per L, 60 min, 42.5°C	28.6 mo (0.4-72 mo)	-	-	-	-	97
Cavaliere et al[97]	69	2003	Phase II	CRC	MMC	-	-	-	27	-	-
Glehen et al[66]	506	2004	Phase II	CRC	MMC/LOHP, 40°C-43°C, 30-90 min	53 mo	72	-	39	-	19
Verwaal et al[98]	117	2005	Phase II	CRC	MMC 35 mg/m2, 40°C-41°C, 90 min	46 mo	75	-	28	-	19
Sugarbaker et al[72]	70	2006	Phase II	CRC	MMC	47 mo	88	-	44	-	32
Helm et al[99]	5	2007	Retrospective review	Recurrent endometrial ca	CDDP 100 mg/m2, 41°C-43°C, 90 min	36 mo	80	80	80	80	-
Zanon et al[100]	25	2006	Phase II	CRC	MMC 15 mg/m2, 42°C, 60 min	36 mo	64	40	-	-	-
Piso et al[101]
	19	2004	-	OC	CDDP 75 mg/m2, or mitoxantrone 15 mg/m2, 41.5°C, 90 min	-	-	-	-	-	15
Roviello et al[102]	59	2006	-	OC, CRC, GC, Pseudomyxoma, Mesothelioma	MMC 25 mg/m2, CDDP 100 mg/m2. (LOHP 460 mg/m2 in 4 pts with colorectal PC), 41°C-43°C, 60 min	25 ± 21 mo	-	-	-	-	50.8

GC: Gastric cancer; CRC: Colorectal cancer; OC: Ovarian cancer; MMC: Mitomycin C; CDDP: Cisplatin; LOHP: Oxaliplatin.